β-内酰胺酶抑制剂复方制剂临床应用分析

Analysis of Compound Preparations of β-Lactamase Inhibitors in Clinical Application

目的:分析本院2002年～2004年β-内酰胺酶抑制剂复方制剂临床用药情况.方法:通过DDDs和日均费用以及各种分类DDDs和金额进行分析.结果:头孢哌酮舒巴坦钠金额和DDDs均排第1,3年的金额和DDDs均占此类药物49%以上,其次是阿莫西林克拉维酸钾,DDDs占22%以上,两者之和占77%以上.粉针剂金额占主导.临床应用主要是含舒巴坦的药物.头孢菌素类占多数,且每年有所上升.结论:β-内酰胺酶抑制剂复方制剂在临床应用中占重要地位,是解决细菌对这类药物耐药性的关键.

OBJECTIVE： To analyze the condition of compound preparations of β - lactamase inhibitors in clinical application in our hospital during the period 2002 - 2004. METHODS： By taking DDDs, daily cost, DDDs and amount of money of each kind of compound preparation to make an analysis. RESULTS ： Cefoperazone sulbactam sodium ranked first in amount of money and DDDs, total amount of money and DDDs of 3 years took up over 49% of this kind of drug. Amoxicillin potassium clavulanate ranked second, its DDDs took up over 22 %. DDDs of this two kinds of drugs took up over 77 % . Amount of money was mainly spent on injectable powder. Drugs containing sulbactam were mainly used in the clinic, cephalosporins took majority. Their using rate increased year by year. CONCLUSION： Compound preparations of β - lactamase inhibitors have occupied an important place in clinical application, they have played key role in solving drug resistance of this kind of drug to bacterium.